American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Division
        • AHNS Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Fellowship Curriculum for FY2024-2025
      • For Current AHNS Fellows
      • Certificate of Completion Request
    • Accredited Fellowships
      • Directory of Fellowships
      • AHNS Fellowship Match
      • Fellowship Curriculum
      • Fellowship Graduates
      • For Program Directors
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
      • Head and Neck Reconstruction- Information for Patients
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland Section
      • Salivary Gland Section Patient Education Handout: Parotidectomy
    • Cutaneous Cancer
  • Find-A-Physician
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Login
    • Password Reset
  • Donate

Published on February 2, 2024 by

Nicole Schmitt – Atlanta Georgia

← Go back

Nicole Schmitt

Winship Cancer Institute at Emory University

  • 25
  • 18

550 Peachtree Street Northeast
11th Floor Otolaryngology
Atlanta, Georgia 30308
United States
Map It

Nicole C. Schmitt, MD, FACS, is an Acting Associate Professor in the Department of Otolaryngology and Co-Director for Translational Research in the Head and Neck Program at Winship Cancer Institute and Emory University School of Medicine. A board certified otolaryngologist, Dr. Schmitt's clinical and research work is focused on head and neck surgical oncology and novel therapeutic combinations. Dr. Schmitt is a Fellow of the American College of Surgeons, American Academy of Otolaryngology Head and Neck Surgery, and American Head and Neck Society.

 

Dr. Schmitt obtained her Medical Degree from Washington University School of Medicine in St. Louis, Missouri. She completed her general surgery internship, a research fellowship and her residency in otolaryngology at University of Washington in Seattle, Washington. She also completed a fellowship in head and neck surgery and tumor biology at University of Pittsburgh in Pittsburgh, Pennsylvania. Dr. Schmitt was on faculty at Johns Hopkins University and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, before joining the faculty at Emory University in 2020.

 

Dr. Schmitt's research interest is in characterizing immune effects of cytotoxic chemotherapy and designing optimal combinations of chemotherapy and immunotherapy for head and neck cancer.

ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C, Schmitt NC. Oncoimmunology. 2020 Jan 9;9(1):1710398.

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC. Oral Oncol. 2019 Aug;95:127-135.

Cisplatin alters anti-tumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC. Cancer Immunol Res 2017;5: 1141-1151.

PD-1 inhibition minimally impacts cisplatin-induced toxicities in a murine model. Spielbauer K, Cunningham L, Schmitt N. Otolaryngol Head and Neck Surg 2018; 159:343-346.

Antagonist of cIAP1/2 and XIAP synergizes with radiation therapy and PD-1 blockade to enhance anti-tumor immunity. Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Oncoimmunology 2018; 7:e1471440.

Related

© 2002–2025 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc